Optiver Holding’s TG Therapeutics TGTX Stock Holding History

Optiver Holding’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.6K	Buy	+1,121	New	+$45.9K	﹤0.01%	1120
2026 Q1	–	Sell	-88	Closed	-$2.62K	–	2725
2025 Q4	$2.62K	Sell	88 -665	-88%	-$21.7K	﹤0.01%	1853
2025 Q3	$27.2K	Buy	753 +732	+3,486%	+$24.1K	﹤0.01%	891
2025 Q2	$756	Sell	21 -202	-91%	-$7.52K	﹤0.01%	1393
2025 Q1	$8.79K	Buy	+223	New	+$7.5K	﹤0.01%	929
2024 Q3	–	Sell	-2,495	Closed	-$44.4K	–	1092
2024 Q2	$44.4K	Buy	+2,495	New	+$39.8K	﹤0.01%	574

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Optiver Holding's TGTX Position: Q2 2026 in Review

Optiver Holding opened a new position in TG Therapeutics (TGTX) in Q2 2026: 1,121 shares worth $61.6K. The stake represents ﹤0.01% of the portfolio and ranks #1120 among its holdings. This is a return to the name: Optiver Holding previously reported a position in TGTX as recently as Q4 2025.

Optiver Holding first reported a position in TGTX in Q2 2024 and has held it in 6 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Optiver Holding held 1,121 shares of TG Therapeutics worth $61.6K as of Q2 2026.
TG Therapeutics was a new Optiver Holding position in Q2 2026.
TG Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1120 holding.
Optiver Holding first reported a position in TG Therapeutics in Q2 2024 and has held it in 6 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.